Tocagen On The Rocks With Phase III Brain Cancer Study Failure

Phase III CORE and CORE2 results presented at the AHA meeting in severe hypertriglyceridemia showed durable triglyceride lowering and reductions in acute pancreatitis across patient subgroups, supporting expansion of Tryngolza (olezarsen) into a second, larger indication.

Cardiologists know PCSK9 inhibition is a powerful LDL-lowering tool and now Amgen’s VESALIUS data show it may be worth adding to the primary care physician’s toolbox for prevention of high-risk patients’ first major cardiovascular events.

The US pharma giant may have a best-in-class amylin agonist to go with incretin blockbuster Zepbound, but challengers could still go one better on safety and tolerability.

Pivotal data next year will be key for the early-stage biotech as analysts remain divided on ORX750's potential.